Effects of different dose of FK506 on endocrine function of pancreatic islets and damage of beta cells of pancreatic islets in a Wistar rat model.
OBJECTIVE
To probe into the effects of different doses of FK506 on endocrine function of pancreatic islets in Wistar rats.


METHODS
Wistar rats were randomly divide into control group A (0mg/kg/d) and experimental group B (1mg/kg/d), C (3mg/kg/d), D (10mg/kg/d) treated with FK506. In an intraperitoneal glucose tolerance test, plasma glucose, insulin and C-peptide were measured with a glucose analyzer and ELISA. The ultra-structure of beta cells of pancreatic islets were assayed with an electric microscope.


RESULTS
In the intraperitoneal glucose tolerance test, the level of plasma glucose increased with an increasing of dose of FK506 and the level of plasma insulin and C-peptide decreased with an increasing of dose of FK506. The result of the plasma glucose level showed no significant difference among groups A, B, C, and D at 0 and 120 min P>or=0.05, and result of plasma glucose level show significant differences among groups A, B, C, D at 30, 60 and 90 min, P<0.05. The result of the plasma insulin level showed significant difference among groups A, B, C, and D at 0, 30, 60, 90 min P<0.05.The result of the plasma C-peptide level showed no significant difference among groups A, B, C, and D at 0 min P> 0.05, and the result of plasma C-peptide level showed significant differences in groups A, B, C, and D at 30, 60, 90 and 120 min, P<0.05.With electric microscope assay, the endocrine secretory granules decreased in experiment group. There is some vacuolization in the beta cells of pancreatic islets in group D.


CONCLUSIONS
It was shown in the study that disorders of glucose metabolism induced by FK506 were related to the dosage of FK506.
Li
Feng
F
Department of chemical institute, Binzhou Medical University, Binzhou City, Shandong Province, China.
Li
QingYuan
Q
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D005951:Glucose Tolerance Test; D006943:Hyperglycemia / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007328:Insulin / Q000097:blood; D050417:Insulin-Secreting Cells / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D007515:Islets of Langerhans / Q000187:drug effects* / Q000378:metabolism / Q000648:ultrastructure; D008297:Male; D046529:Microscopy, Electron, Transmission; D051381:Rats; D017208:Rats, Wistar; D016559:Tacrolimus / Q000009:adverse effects*
D001786:Blood Glucose; D002096:C-Peptide; D007166:Immunosuppressive Agents; D007328:Insulin; D016559:Tacrolimus